MicroRNA-155 Functions as an OncomiR in Breast Cancer by Targeting theSuppressor of Cytokine Signaling 1Gene
Top Cited Papers
- 14 April 2010
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 70 (8), 3119-3127
- https://doi.org/10.1158/0008-5472.can-09-4250
Abstract
MicroRNA-155 (miR-155) is overexpressed in many human cancers; however, the mechanisms by which miR-155 functions as a putative oncomiR are largely unknown. Here, we report that the tumor suppressor gene suppressor of cytokine signaling 1 (socs1) is an evolutionarily conserved target of miR-155 in breast cancer cells. We found that mir-155 expression is inversely correlated with socs1 expression in breast cancer cell lines as well as in a subset of primary breast tumors. We also identified a 24A→G mutation in the miR-155 binding site of the SOCS1 3′ untranslated region in a breast tumor that reduced miR-155 repression, implicating a mechanism for miRNA targets to avoid repression. Ectopic expression of miR-155 significantly promoted the proliferation of breast cancer cells, the formation of soft agar foci in vitro, and the development of tumors in nude mice. In breast cancer cells, RNA interference silencing of socs1 recapitulates the oncogenic effects of miR-155, whereas restoration of socs1 expression attenuates the protumorigenesis function of miR-155, suggesting that miR-155 exerts its oncogenic role by negatively regulating socs1. Overexpression of miR-155 in breast cancer cells leads to constitutive activation of signal transducer and activator of transcription 3 (STAT3) through the Janus-activated kinase (JAK) pathway, and stimulation of breast cancer cells by the inflammatory cytokines IFN-γ and interleukin-6 (IL-6), lipopolysaccharide (LPS), and polyriboinosinic:polyribocytidylic acid [poly(I:C)] significantly upregulates mir-155 expression, suggesting that miR-155 may serve as a bridge between inflammation and cancer. Taken together, our study reveals that miR-155 is an oncomiR in breast cancer and that miR-155 may be a potential target in breast cancer therapy. Cancer Res; 70(8); 3119–27. ©2010 AACR.Other Versions
This publication has 35 references indexed in Scilit:
- Widespread Shortening of 3′UTRs by Alternative Cleavage and Polyadenylation Activates Oncogenes in Cancer CellsCell, 2009
- MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cellsProceedings of the National Academy of Sciences of the United States of America, 2009
- MicroRNAs: Target Recognition and Regulatory FunctionsCell, 2009
- Foxp3-Dependent MicroRNA155 Confers Competitive Fitness to Regulatory T Cells by Targeting SOCS1 ProteinImmunity, 2009
- MicroRNA target site polymorphisms and human diseaseTrends in Genetics, 2008
- MicroRNA-155 Is a Negative Regulator of Activation-Induced Cytidine DeaminaseImmunity, 2008
- Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor developmentProceedings of the National Academy of Sciences of the United States of America, 2007
- Requirement of bic/microRNA-155 for Normal Immune FunctionScience, 2007
- MicroRNA-155 is induced during the macrophage inflammatory responseProceedings of the National Academy of Sciences of the United States of America, 2007
- Oncomirs — microRNAs with a role in cancerNature Reviews Cancer, 2006